Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Thursday, September 10, 2026

Back to today

From X

@orrdavid

David Orr on X

$SOXX made a sharp dive in from June 30th to July 29th. The fact that it still hasn't recovered a month and a half later makes this look a lot more like a 2000's twilight-before-the-collapse market than a 1999 bear trap. Put that another way: On a sharp sell off, you can easily point to technical / positioning factors being the cause. Situational Awareness's blow up could have been a textbook example. But it's just not working that way. In fact, we had a sharp sell off, and there's seemingly no fuel for a rebound despite AI improvement news seeming to come out strong. Markets have wisdom to them. It's worth listening, bull or bear. Right now, the set up seems super bearish, like the market knows there is a problem with AI. And the most likely problem I see is that there's simply no sites available to build more electricity-hungry compute centers. Someone smart I talked with recently pointed out politics could block AI as well ... which could exasberate that problem a bit by individual small local areas or by state and possibly by country. But I still think the root issue here is just not enough electricity, there's simple a hard barrier in the world of atoms that takes many years to resolve.
@leevalueroach

Lee Roach on X

I wrote up $APP. Gave it my thoughts. I think it is one of the best business models in the world. And if they can successfully get into the e-commerce space then there is a ton of white space for growth. Found a decent way to track their move to e-commerce too which I don't think many are doing. I am not buying here as this is like a 4% free cash flow yield. But this stock is volatile and I plan to take advantage of any sort of downturn and freak out price drop, which tends to happen in this industry. Putting it on my watch list. Have a read if you like ad-tech space. I find it fascinating.

Investor Letters

All letters

Lululemon: Deep Dive Analysis

Lululemon’s Q2 revenue fell 4% and Americas comparable sales 12%, as markdowns, tariffs and activewear rivals pressure its premium apparel…

LULU $11B
Hated Moats 6 clicks
IQV · long

Iqvia Holdings INC

IQVIA runs drug trials and gets paid regardless of whether drugs pass, while trading at a COVID-low multiple with potential AI benefits.

IQV $44B
Value Investors Club 1 click

Checking Out Music Royalties

Mills Music Trust's 8.5% yield faces declining distributions as songs enter the public domain, while Royalty Exchange lists more than 700…

MMTRS
Exploring with Alluvial Capital

Sarepta Risk and the FDA

Sarepta’s Exondys 51 approval despite a 12-patient trial frames FDA regulatory risk and a call to remove Commissioner Robert Califf.

SRPT $2.2B
John Hempton's Newsletter 1 click

Publications we follow

Every publication on this site, hand-picked.

108 publications

Newsletters 91

YouTube 4

Blogs 12

Seeking Alpha 31 of 170

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

71 accounts
Nominate an account

Investor letters we follow

78 firms

Sectors

Ordered by how often our editor reaches for them.